FindTrial
Sign In

A pilot study comparing efficacy and safety of topical 3% minoxidil solution with topical 3% minoxidil solution combined with topical 0.25% finasteride solution in treatment of female pattern hair loss.

A pilot study comparing efficacy and safety of topical 3% minoxidil solution with topical 3% minoxidil solution combined with topical 0.25% finasteride solution in treatment of female pattern hair loss.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160912002
Enrollment
30
Registered
2016-09-12
Start date
2015-09-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female pattern hair loss Androgenetic alopecia

Interventions

Topical 3% minoxidil solution combined with 0.25% finasteride solution,Topical 3% minoxidil solution
Experimental Drug,Active Comparator Drug

Sponsors

Division of Dermatology, Ramathibodi Hospital, Mahidol University
Lead Sponsor
Division of Dermatology&#44
Collaborator
Ramathibodi Hospital&#44
Collaborator
Mahidol University
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1.Healthy female subject 2.Diagnosis of female pattern hair loss 3.Agree to participate and signed informed consent form

Exclusion criteria

Exclusion criteria: 1.History of hair transplant 2.Applying topical hair growth products within 2 weeks 3.Receiving light and laser treatment of the scalp within 3 months 4.Taking oral finasteride within 12 months 5.Taking dutasteride within 18 months 6.History of systemic illness 7.History of scalp diseases eg. seborrheic dermatitis, scalp infection. 8.Pregnancy or breast feeding

Design outcomes

Primary

MeasureTime frame
Efficacy of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Hair count and hair diameter—

Secondary

MeasureTime frame
Safety of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Erythema, Scaliness, Inflammation and Systemic side effects—

Countries

Thailand

Contacts

Public ContactPoonkiat Suchonwanit

Ramathibodi Hospital, Mahidol University

poonkiat@hotmail.com0817348580

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026